Radius Health Inc. | Mutual Funds
Mutual Funds that own Radius Health Inc.
BB Biotech AG
5,853,799
12.87%
355,000
2.9%
03/31/2018
SPDR S&P Biotech ETF
2,266,450
4.98%
5,832
0.8%
09/06/2018
T Rowe Price Small Cap Stock Fund
1,331,765
2.93%
-8,100
0.26%
06/30/2018
Fidelity Select Biotechnology Portfolio
1,075,428
2.37%
-129,887
0.24%
07/31/2018
Vanguard Small Cap Index Fund
1,027,560
2.25%
11,937
0.02%
07/31/2018
Vanguard Total Stock Market Index Fund
1,009,237
2.22%
1,012
0%
07/31/2018
iShares Russell 2000 ETF
846,865
1.86%
-453
0.04%
09/06/2018
Oppenheimer International Small Company Fund
825,980
1.82%
825,980
0.16%
02/28/2018
T Rowe Price Health Sciences Fund
800,368
1.76%
-272,134
0.13%
06/30/2018
T Rowe Price Institutional Small Cap Stock Fund
634,400
1.4%
0
0.26%
06/30/2018
| Address |
950 Winter Street
Waltham Massachusetts 02451
United States
|
|
Employees
|
- |
| Website |
http://www.radiuspharm.com |
| Updated |
07/08/2019 |
| Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The firm's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. |
